Literature DB >> 16648112

Oncopaz cooperative group.

Manuel González Barón, Enrique Espinosa.   

Abstract

Mesh：

Year:  2006        PMID： 16648112     DOI： 10.1007/s12094-006-0003-2

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


× No keyword cloud information.
  22 in total

1.  Phase II study of cisplatin, 5-fluorouracil, and leucovorin in inoperable squamous cell carcinoma of the esophagus. ONCOPAZ Cooperative Group, Spain.

Authors:  J Feliu; M González Barón; C García Girón; E Espinosa; J M Vicent; J Gómez Navarro; A Berrocal; A Ordóñez; Y Vilches; J de Castro; J Díaz
Journal:  Am J Clin Oncol       Date:  1996-12       Impact factor: 2.339

2.  Biweekly regimen of cisplatin, gemcitabine and vinorelbine for advanced non-small-cell lung cancer.

Authors:  Javier Castro de Carpeño; M González Barón; J Aguiar; J I Chacón; J Feliu; M J García; C Madroñal; A Colmenarejo; J J Sánchez; A Ordóñez
Journal:  Cancer Chemother Pharmacol       Date:  2005-11-25       Impact factor: 3.333

3.  Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas.

Authors:  J Feliu; R Mel; P Borrega; L López Gómez; P Escudero; J Dorta; J Castro; S E Vázquez-Estévez; M Bolaños; E Espinosa; M González Barón
Journal:  Ann Oncol       Date:  2002-11       Impact factor: 32.976

4.  Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group.

Authors:  J Feliu; M González Barón; E Espinosa; C García Girón; I de la Gándara; J Espinosa; A Colmenarejo; J I Jalón; Y Fernández; J de Castro
Journal:  Cancer       Date:  1997-05-15       Impact factor: 6.860

5.  Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy.

Authors:  Manolo González-Barón; Amdio Ordóñez; Rosa Franquesa; Manuel Constenla; Joaquin Montalar; Frederic Gili; Carlos Camps; José Felix Sancho; Pedro Pérez-Cachot
Journal:  Cancer       Date:  2002-12-01       Impact factor: 6.860

6.  Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Oncopaz Cooperative Group.

Authors:  J Feliu; L López Gómez; C Madroñal; E Espinosa; J Espinosa; C G Girón; B Martínez; J Castro; I De la Gándara; M G Barón
Journal:  Cancer       Date:  1999-10-15       Impact factor: 6.860

7.  Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: an active and low toxicity regimen.

Authors:  J Feliu; J R Mel; C Camps; P Escudero; J Aparicio; D Menéndez; C García Girón; M R Rodriguez; J J Sánchez; M González Barón
Journal:  Eur J Cancer       Date:  2002-06       Impact factor: 9.162

8.  Treatment of advanced gastric cancer with the combination fluorouracil, leucovorin, etoposide, and cisplatin: a phase II study of the ONCOPAZ Cooperative Group.

Authors:  M González-Barón; J Feliu; E Espinosa; C García-Girón; I Chacón; P Garrido; A Colmenarejo; A Ordóñez; P Zamora
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  Treatment of metastatic malignant melanoma with cisplatin plus tamoxifen.

Authors:  J Feliu; M González Barón; J I Chacón; E Espinosa; P Garrido; J Castro; Y Escobar; A Colmenarejo; C Jara; C García Girón; J Espinosa; A Ordóñez
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

10.  Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer.

Authors:  J Feliu; C Castañón; A Salud; J R Mel; P Escudero; A Pelegrín; L López-Gómez; M Ruiz; E González; F Juárez; J Lizón; J Castro; M González-Barón
Journal:  Br J Cancer       Date:  2005-11-28       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.